In this photo illustration the American multinational pharmaceutical corporation Pfizer logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.
Budrul Chukrut | SOPA Images | Getty Images
Pfizer shares jumped by nearly 7% in premarket trading Wednesday after it released positive results from its closely watched early-stage human trial on a coronavirus vaccine.
The trial evaluated 45 people. Each participant received either a 10, 30 or 100 microgram dose of the vaccine or a placebo.
The company coronavirus vaccine produced neutralizing antibodies, which researchers say is important for acquiring protection, in all participants who received the 10 or 30 microgram dose after 28 days, according to the preliminary data, which were posted in a paper released on MedRXiv.
The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech. The company’s experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response for the virus.
This is a developing story. Please check back for updates.
No comments:
Post a Comment